Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) Gross Profit (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Gross Profit for 4 consecutive years, with $183.7 million as the latest value for Q4 2025.

  • Quarterly Gross Profit rose 1934.13% to $183.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $591.0 million through Dec 2025, up 152.44% year-over-year, with the annual reading at $591.0 million for FY2025, 67.72% up from the prior year.
  • Gross Profit hit $183.7 million in Q4 2025 for Axsome Therapeutics, up from $159.1 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $183.7 million in Q4 2025 to a low of -$10.0 million in Q4 2024.
  • Historically, Gross Profit has averaged $74.3 million across 4 years, with a median of $68.7 million in 2024.
  • Biggest five-year swings in Gross Profit: plummeted 115.61% in 2024 and later skyrocketed 1934.13% in 2025.
  • Year by year, Gross Profit stood at $22.1 million in 2022, then skyrocketed by 190.54% to $64.2 million in 2023, then tumbled by 115.61% to -$10.0 million in 2024, then surged by 1934.13% to $183.7 million in 2025.
  • Business Quant data shows Gross Profit for AXSM at $183.7 million in Q4 2025, $159.1 million in Q3 2025, and $136.6 million in Q2 2025.